# Cardiovascular disease therapeutics via engineered oral microbiota: Applications and perspective

## TL;DR

This paper explores using engineered oral bacteria as a new treatment approach for cardiovascular diseases.

## Contribution

It highlights the potential of genetically modifying oral bacteria to secrete therapeutic molecules for cardiovascular disease treatment.

## Key findings

- Engineered oral bacteria can be modified to produce therapeutic effects via plasmid incorporation.
- Genetically engineered probiotics can secrete cytokines and reactive oxygen species for novel cardiovascular therapies.
- Oral microbiota engineering shows promise for treating cardiovascular diseases and related risk factors.

## Abstract

Engineering bacteria are considered as a potential treatment for cardiovascular diseases and related risk factors. Oral bacteria are closely related to the occurrence and development of cardiovascular diseases, and their engineering has broad prospects and potential in the treatment of cardiovascular diseases. Oral pathogenic bacteria undergo protein and genetic engineering, including the incorporation of exogenous plasmids to yield therapeutic effects; genetically engineered oral probiotics can be harnessed to secrete cytokines and reactive oxygen species, offering novel therapeutic avenues for cardiovascular diseases.